再生元制药

Regeneron: Canaccord Genuity raises PT to $1057 from $850 with Buy rating.

BMO Capital raises Regeneron PT to $850 from $725, maintains Outperform rating.

Regeneron

Morgan Stanley

Regeneron Pharmaceuticals Downgraded to Equal-Weight by Morgan Stanley.

Regeneron's stock experiences MACD Death Cross and Bollinger Bands expanding downward.

Morgan Stanley Downgrades Regeneron to Equal-Weight, Raises Price Target to $767.

Catalyst<ul> <li>Positive fund flow trends across all order sizes indicate broad investor confidence in REGN.</li></ul>Risk<ul> <li>Technical indicators show a weak market state with bearish signals dominating, suggesting a risk of further decline.</li> <li>Analyst ratings remain inconsistent, with three Neutral and two Strong Buy ratings, highlighting uncertainty in institutional outlook.</li></ul>

Key Factors

Regeneron Pharmaceuticals collaborates with Tessera Therapeutics to develop TSRA-196, an in vivo gene-editing therapy for Alpha-1 Antitrypsin Deficiency. Morgan Stanley downgrades Regeneron to equal-weight, citing fair valuation and raising its price target to $767. Canaccord Genuity maintains a buy rating on Regeneron and raises its price target to $1057 from $850. BMO Capital raises Regeneron's price target to $850 from $725 and maintains its outperform rating.

Recent Updates

REGN News